TABLE 1.
Bacterial strains and plasmids used in this study
| Strain or plasmid | Description | Reference or source |
|---|---|---|
| E. coli | ||
| DH5α | hsdR recA lacZYAπ80 lacZΔM15 | Laboratory collection |
| SM10λpir | thi thr leu tonA lacY supE recA::RP4-2-Tc::Muλpir R6K | 29 |
| V. parahaemolyticus | ||
| TH3996 | Clinical isolate, trh+ure+ | 34 |
| 3996-M1 | TH3996, vpaH disrupted | This study |
| 3996-M2 | TH3996, lafTU disrupted | This study |
| 3996-C1 | 3996-M1, vpaH complemented | This study |
| RIMD2212189 | Clinical isolate, KP positive, tdh+vpaH deficient | RIMDa |
| RIMD2212189-1 | RIMD2212189 with the vpaH gene introduced | This study |
| Plasmid | ||
| pUC119 | Cloning vector, Apr | 49 |
| pT7Blue T-vector | Multicopy (ColE1 ori) TA cloning vector, Apr | Novagen, Inc. |
| pYAK1 | Suicide vector, R6Kori, sacB, Cmr | 22 |
| pSA19CP | Plasmid vector derived from V. parahaemolyticus, Cmr | 30 |
| pKS-1 | 1.8-kb SpeI fragment cloned into the XbaI site on pUC119 | This study |
| pKS-2 | pSA19CP introduced with the PCR-amplified TH3996 vpaH gene | This study |
a
RIMD, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.